A Comprehensive Review on Patents, Herbal Treatment and Clinical Trials on Acquired Immune Deficiency Syndrome


Cite item

Full Text

Abstract

This paper provides an outline of the Human immunodeficiency virus (HIV), its mechanism of action, and types of HIV/AIDS. Additionally, it offers recent advances and patent data on HIV medications and formulations for the last ten years. The HIV/AIDS patents describes how compounds can stop viruses from spreading and stop HIV from multiplying. It also gives information about monolithic tablets, fixed oral doses of triple HIV formulations, and drug delivery systems that use electrospun fibers. The patents also reveals the treatment for patients having liver disease by using herbal ingredients. The effects of various herbal ingredients and preparations on HIV replication, immunological function, and symptom management have been researched. Despite the encouraging randomized trial data available, it is crucial to proceed cautiously when using herbal treatments for HIV/AIDS treatment. Recent years clinical trials of HIV/AIDS were also reviewed. Herbal remedies are preferred more than other drugs because they have fewer side effects and have long-lasting effects for the treatment of HIV/AIDS. The regulation, quality assurance, and standardization of herbal products are the challenges for the industry.

About the authors

Sushen Choudhary

Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute)

Email: info@benthamscience.net

Sushma Verma

Department of Pharmaceutics, Noida Institute of Engineering and Technology (Pharmacy Institute)

Author for correspondence.
Email: info@benthamscience.net

References

  1. Jin, H.; Chong, H.; Zhu, Y.; Zhang, M.; Li, X.; Bazybek, N.; Wei, Y.; Gong, F.; He, Y.; Ma, G. Preparation and evaluation of amphipathic lipopeptide-loaded PLGA microspheres as sustained-release system for AIDS prevention. Eng. Life Sci., 2020, 20(11), 476-484. doi: 10.1002/elsc.202000026 PMID: 33204234
  2. Jenita, J.; Wilson, B.; Chocalingam, V. Albumin nanoparticles coated with polysorbate 80 as a novel drug carrier for the delivery of antiretroviral drug-Efavirenz. Int. J. Pharm. Investig., 2014, 4(3), 142-148. doi: 10.4103/2230-973X.138348 PMID: 25126528
  3. Ghosh, A.K.; Osswald, H.L.; Prato, G. Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV/AIDS. J. Med. Chem., 2016, 59(11), 5172-5208. doi: 10.1021/acs.jmedchem.5b01697 PMID: 26799988
  4. Piot, P.; Abdool Karim, S.S.; Hecht, R.; Legido-Quigley, H.; Buse, K.; Stover, J.; Resch, S.; Ryckman, T.; Møgedal, S.; Dybul, M.; Goosby, E.; Watts, C.; Kilonzo, N.; McManus, J.; Sidibé, M. Defeating AIDS-advancing global health. Lancet, 2015, 386(9989), 171-218. doi: 10.1016/S0140-6736(15)60658-4 PMID: 26117719
  5. Silverberg, M.J.; Lau, B.; Achenbach, C.J.; Jing, Y.; Althoff, K.N.; D’Souza, G.; Engels, E.A.; Hessol, N.A.; Brooks, J.T.; Burchell, A.N.; Gill, M.J.; Goedert, J.J.; Hogg, R.; Horberg, M.A.; Kirk, G.D.; Kitahata, M.M.; Korthuis, P.T.; Mathews, W.C.; Mayor, A.; Modur, S.P.; Napravnik, S.; Novak, R.M.; Patel, P.; Rachlis, A.R.; Sterling, T.R.; Willig, J.H.; Justice, A.C.; Moore, R.D.; Dubrow, R. Cumulative incidence of cancer among persons with HIV in North America: A cohort study. Ann. Intern. Med., 2015, 163(7), 507-518. doi: 10.7326/M14-2768 PMID: 26436616
  6. Flexner, C.; Thomas, D.L.; Swindells, S. Creating demand for long-acting formulations for the treatment and prevention of HIV, tuberculosis, and viral hepatitis. Curr. Opin. HIV AIDS, 2019, 14(1), 13-20. doi: 10.1097/COH.0000000000000510 PMID: 30394948
  7. Uckun, FM; Qazi, S; Venkatachalam, TK In vitro anti-HIV potency of Stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung., 2005, 55(4), 223.
  8. Cattaneo, D.; Andreoni, M.; Carosi, G.; Cauda, R.; Lazzarin, A.; Rizzardini, G. Generic antiretrovirals for the treatment of HIV: A novel challenge for Western countries?. Int. J. Clin. Pharmacol. Ther., 2017, 55(5), 381-393. doi: 10.5414/CP202775 PMID: 28211784
  9. Napper, L.E.; Fisher, D.G.; Reynolds, G.L.; Johnson, M.E. HIV risk behavior self-report reliability at different recall periods. AIDS Behav., 2010, 14(1), 152-161. doi: 10.1007/s10461-009-9575-5 PMID: 19475504
  10. Vickers, A. Recent advances: Complementary medicine. BMJ, 2000, 321(7262), 683-686. doi: 10.1136/bmj.321.7262.683 PMID: 10987776
  11. Özsoy, M.; Ernst, E. How effective are complementary therapies for HIV and AIDs?--A systematic review. Int. J. STD AIDS, 1999, 10(10), 629-635. doi: 10.1258/0956462991913088 PMID: 10582628
  12. Nyamweya, S.; Hegedus, A.; Jaye, A.; Rowland-Jones, S.; Flanagan, K.L.; Macallan, D.C. Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Rev. Med. Virol., 2013, 23(4), 221-240. doi: 10.1002/rmv.1739 PMID: 23444290
  13. Sharp, P.M.; Hahn, B.H. Origins of HIV and the AIDS Pandemic. Cold Spring Harb. Perspect. Med., 2011, 1(1), a006841. doi: 10.1101/cshperspect.a006841 PMID: 22229120
  14. Esbjörnsson, J.; Månsson, F.; Kvist, A.; Isberg, P.E.; Nowroozalizadeh, S.; Biague, A.J.; da Silva, Z.J.; Jansson, M.; Fenyö, E.M.; Norrgren, H.; Medstrand, P. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. N. Engl. J. Med., 2012, 367(3), 224-232. doi: 10.1056/NEJMoa1113244 PMID: 22808957
  15. Peterson, K.; Ruelle, J.; Vekemans, M.; Siegal, F.P.; Deayton, J.R.; Colebunders, R. The role of raltegravir in the treatment of HIV-2 infections: Evidence from a case series. Antivir. Ther., 2012, 17(6), 1097-1100. doi: 10.3851/IMP2303 PMID: 22892365
  16. Peterson, K.; Jallow, S.; Rowland-Jones, S.L.; de Silva, T.I. Antiretroviral therapy for HIV-2 infection: Recommendations for management in low-resource settings. Aids Res. Treat., 2011, 2011, 1-11. doi: 10.1155/2011/463704 PMID: 21490779
  17. Campbell-Yesufu, O.T.; Gandhi, R.T. Update on human immunodeficiency virus (HIV)-2 infection. Clin. Infect. Dis., 2011, 52(6), 780-787. doi: 10.1093/cid/ciq248 PMID: 21367732
  18. Chen, B. Molecular mechanism of HIV-1 entry. Trends Microbiol., 2019, 27(10), 878-891. doi: 10.1016/j.tim.2019.06.002 PMID: 31262533
  19. Harrison, S.C. Mechanism of membrane fusion by viral envelope proteins. Adv. Virus Res., 2005, 64, 231-261. doi: 10.1016/S0065-3527(05)64007-9 PMID: 16139596
  20. Yang, S.S.; Cragg, G.M.; Newman, D.J.; Bader, J.P. Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. J. Nat. Prod., 2001, 64(2), 265-277. doi: 10.1021/np0003995 PMID: 11430019
  21. Ashe, S.; Nayak, D.; Tiwari, G.; Rauta, P.R.; Nayak, B. Development of liposome-encapsulated ketoconazole: Formulation, characterisation and evaluation of pharmacological therapeutic efficacy. Micro & Nano Lett., 2015, 10(2), 126-129. doi: 10.1049/mnl.2014.0198
  22. Elzoghby, A.O. Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of research. J. Control. Release, 2013, 172(3), 1075-1091. doi: 10.1016/j.jconrel.2013.09.019 PMID: 24096021
  23. Nayak, D.; Boxi, A.; Ashe, S.; Thathapudi, N.C.; Nayak, B. Stavudine loaded gelatin liposomes for HIV therapy: Preparation, characterization and in vitro cytotoxic evaluation. Mater. Sci. Eng. C, 2017, 73, 406-416. doi: 10.1016/j.msec.2016.12.073 PMID: 28183626
  24. Magnus, C.; Regoes, R.R. Restricted occupancy models for neutralization of HIV virions and populations. J. Theor. Biol., 2011, 283(1), 192-202. doi: 10.1016/j.jtbi.2011.06.004 PMID: 21683711
  25. Ogunlaran, O.M.; Oukouomi Noutchie, S.C. Mathematical model for an effective management of HIV infection. BioMed Res. Int., 2016, 2016, 1-6. doi: 10.1155/2016/4217548 PMID: 27057541
  26. Curley, P.; Liptrott, N.J.; Owen, A. Advances in nanomedicine drug delivery applications for HIV therapy. Future Sci. OA, 2018, 4(1), FSO230. doi: 10.4155/fsoa-2017-0069 PMID: 29255619
  27. Zazo, H.; Colino, C.I.; Lanao, J.M. Current applications of nanoparticles in infectious diseases. J. Control. Release, 2016, 224, 86-102. doi: 10.1016/j.jconrel.2016.01.008 PMID: 26772877
  28. Tekade, R.K.; Maheshwari, R.; Soni, N.; Tekade, M.; Chougule, M.B. Nanotechnology for the development of nanomedicine.Nanotechnology-based approaches for targeting and delivery of drugs and genes; Elsevier, Inc, 2017, pp. 3-61. doi: 10.1016/B978-0-12-809717-5.00001-4
  29. Caldera, F.; Tannous, M.; Cavalli, R.; Zanetti, M.; Trotta, F. Evolution of cyclodextrin nanosponges. Int. J. Pharm., 2017, 531(2), 470-479. doi: 10.1016/j.ijpharm.2017.06.072 PMID: 28645630
  30. Anandam, S.; Selvamuthukumar, S. Optimization of microwave-assisted synthesis of cyclodextrin nanosponges using response surface methodology. J. Porous Mater., 2014, 21(6), 1015-1023. doi: 10.1007/s10934-014-9851-2
  31. Zainuddin, R.; Zaheer, Z.; Sangshetti, J.N.; Momin, M. Enhancement of oral bioavailability of anti-HIV drug rilpivirine HCl through nanosponge formulation. Drug Dev. Ind. Pharm., 2017, 43(12), 2076-2084. doi: 10.1080/03639045.2017.1371732 PMID: 28845699
  32. Duan, J.; Freeling, J.P.; Koehn, J.; Shu, C.; Ho, R.J.Y. Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles. J. Pharm. Sci., 2014, 103(8), 2520-2529. doi: 10.1002/jps.24046 PMID: 24948204
  33. Rajoli, R.K.R.; Back, D.J.; Rannard, S.; Freel Meyers, C.L.; Flexner, C.; Owen, A.; Siccardi, M. Physiologically based pharmacokinetic modelling to inform development of intramuscular long-acting nanoformulations for HIV. Clin. Pharmacokinet., 2015, 54(6), 639-650. doi: 10.1007/s40262-014-0227-1 PMID: 25523214
  34. Perazzolo, S.; Shireman, L.M.; Koehn, J.; McConnachie, L.A.; Kraft, J.C.; Shen, D.D.; Ho, R.J.Y. Three HIV drugs, atazanavir, ritonavir, and tenofovir, coformulated in drug-combination nanoparticles exhibit long-acting and lymphocyte-targeting properties in nonhuman Primates. J. Pharm. Sci., 2018, 107(12), 3153-3162. doi: 10.1016/j.xphs.2018.07.032 PMID: 30121315
  35. Phelps, B.R.; Rakhmanina, N. Antiretroviral drugs in pediatric HIV-infected patients: Pharmacokinetic and practical challenges. Paediatr. Drugs, 2011, 13(3), 175-192. doi: 10.2165/11587300-000000000-00000 PMID: 21500872
  36. Malati, C.Y.; Golin, R.; O’Brien, L.; Sugandhi, N.; Srivastava, M.; Larson, C.; Phelps, B.R. Pursuing use of optimal formulations for paediatric HIV epidemic control-a look at the use of LPV/r oral pellets and oral granules. J. Int. AIDS Soc., 2019, 22(4), e25267. doi: 10.1002/jia2.25267 PMID: 30983152
  37. Ilomuanya, M.O.; Elesho, R.F.; Amenaghawon, A.N.; Adetuyi, A.O.; Velusamy, V.; Akanmu, A.S. Development of trigger sensitive hyaluronic acid/palm oil-based organogel for in vitro release of HIV/AIDS microbicides using artificial neural networks. Future Journal of Pharmaceutical Sciences, 2020, 6(1), 1. doi: 10.1186/s43094-019-0015-8 PMID: 33241057
  38. Satapathy, D.; Biswas, D.; Behera, B.; Sagiri, S.S.; Pal, K.; Pramanik, K. Sunflower-oil-based lecithin organogels as matrices for controlled drug delivery. J. Appl. Polym. Sci., 2013, 129(2), 585-594. doi: 10.1002/app.38498
  39. Ilomuanya, M.O.; Hameedat, A.T.; Akang, E.N.; Ekama, S.O.; Silva, B.O.; Akanmu, A.S. Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis. Future Journal of Pharmaceutical Sciences, 2020, 6(1), 81. doi: 10.1186/s43094-020-00093-3 PMID: 33241057
  40. Nalini, M.V.S.S.; Veni, P.R.K.; Babu, B.H. Determination of Darunavir and cobicistat simultaneously using stability indicating RP-HPLC method. Marmara Pharm. J., 2016, 20(3), 293-302. doi: 10.12991/mpj.20162036176
  41. Dalvadi, H.P.; Desai, S.; Jat, R.K.; Dalwadi, H. Spectrophotometric METHOD DEVELOPMENT AND VALIDATION ON atazanavir AND cobicistat IN ITS BINARY MIXTURE Solubility Enhancement techniques View project estimation of pitavastatin calcium tablet dosage form by liquid chromatography and ultraviolet spectrophotometry View project spectrophotometric METHOD DEVELOPMENT AND VALIDATION ON atazanavir AND cobicistat IN ITS BINARY MIXTURE., Available from: https://www.researchgate.net/publication/362709074
  42. Singh, V.D.; Daharwal, S.J. Development and validation of multivariate calibration methods for simultaneous estimation of Paracetamol, Enalapril maleate and hydrochlorothiazide in pharmaceutical dosage form. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2017, 171, 369-375. doi: 10.1016/j.saa.2016.08.028 PMID: 27569769
  43. Devi Singh, V.; Kumar Singh, V. Chemo-metric assisted UV-spectrophotometric methods for simultaneous estimation of Darunavir ethanolate and Cobicistat in binary mixture and their tablet formulation. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2021, 250, 119383. doi: 10.1016/j.saa.2020.119383 PMID: 33422867
  44. Williams, J.; Sayles, H.R.; Meza, J.L.; Sayre, P.; Sandkovsky, U.; Gendelman, H.E.; Flexner, C.; Swindells, S. Long-acting parenteral nanoformulated antiretroviral therapy: Interest and attitudes of HIV-infected patients. Nanomedicine, 2013, 8(11), 1807-1813. doi: 10.2217/nnm.12.214 PMID: 23611617
  45. Bailon, L.; Mothe, B.; Berman, L.; Brander, C. Novel approaches towards a functional cure of HIV/AIDS. Drugs, 2020, 80(9), 859-868. doi: 10.1007/s40265-020-01322-y PMID: 32436069
  46. Chavan, KG; Mahajan, KC; Mantry, S; Dnyaneshwar, GS; Vachane, RR; Somnath, SD Advance trend in novel formulation of nevirapine conjugated nanoemusion for antiretroviral medications. J Pharm Neg Results, 13.,
  47. Aurobindo, M.H.U. Pharmaceutical composition of Antiretroviral. United States patent US; 2011/0104267 A1,,
  48. Adeyeye, M.C.; Esseku, F.; Joshi, A. Antiretroviral drug formulations for treatment of children exposed to HIV/AIDS. United States patent application US.,, 2011.
  49. Marom, E.; Saba, K.; Rubnov, S.; Aviv, T. Amorphous form of dolutegravir. United States patent US., 2015.
  50. Giardiello, M.; McDonald, T.; Owen, A.; Rannard, S.; Martin, P.; Smith, D. Compositions of lopinavir and ritonavir. United states patent US 9,532.979 B2,, 2017.
  51. Medicament comprising Pharm Comb Dolutegravir Emtricitabine Tenofovir. WO2015/022351 A1,, 2015.
  52. Giardiello, N.M.; Oliver, T.; Paul, S.; John, P. The University of Liverpool assignee. Compos Efavirenz Eur EP. B1:2753314, 2020.
  53. Graham, T.H.; Liu, W.; Yu, T.; Zhang, Y.; Waddell, S.T.; Wai, J.S. Spirocyclic hetercycle compounds useful as HIV integrase inhibitors. US9707234B2, 2017.
  54. Cocklin, S. Composition useful for inhibiting HIV infection. United States patent US 9920073B2, 2018.
  55. Tamura, Y.; Sugiyama, S.; Matsumura, A.; Akiyama, T.; Tomida, Y. Nitrogen-containing tricyclic derivertives having hiv reprication inhibitory activity. TWI700284B, 2020.
  56. Cho, A.; Link, J.; Xu, J. HIV protease inhibitor. United States patent US11318119 B2, 2022.
  57. Woodrow, K.A.; Ball, C.; Blakney, A.; Krogstad, E.; Nie, H. Vaginal matrices: Nanofibers for contraception and prevention of HIV infection. US20140128345A1, 2016.
  58. Zou, W.; Liu, Y.; Wang, J.; Li, H.; Liao, X. Traditional Chinese herbal medicines for treating HIV infections and AIDS. Evid. Based Complement. Alternat. Med., 2012, 2012, 1-8. doi: 10.1155/2012/950757 PMID: 23326295
  59. Wu, J.A.; Attele, A.S.; Zhang, L.; Yuan, C.S. Anti-HIV activity of medicinal herbs: usage and potential development. Am. J. Chin. Med., 2001, 29(1), 69-81. doi: 10.1142/S0192415X01000083 PMID: 11321482
  60. Liu, J. The use of herbal medicines in early drug development for the treatment of HIV infections and AIDS. Expert Opin. Investig. Drugs, 2007, 16(9), 1355-1364. doi: 10.1517/13543784.16.9.1355 PMID: 17714022
  61. Shi, D.; Peng, Z.L. Randomised, double-blind, placebo-controlled clinical study on Qiankunning for HIV/AIDS. China J. Chin. Med., 2003, 21(9), 1472-1474.
  62. Jian, W.; Feng-zhen, Y.; Min, Z.; Yun-hui, Z.; Yong-xiang, Z.; Ying, L.; Wei-min, L.; Fu-sheng, W.; Shu-ling, X.; Zhi-min, Y.; Yan-ming, X.; Xian-zhi, Z.; Tian-jun, I. Randomized double-blinded and controlled clinical trial on treatment of HIV/AIDS by Zhongyan-4. Chin. J. Integr. Med., 2006, 12(1), 6-11. doi: 10.1007/BF02857422 PMID: 16571276
  63. Sangkitporn, S.; Shide, L.; Klinbuayaem, V.; Leenasirimakul, P.; Wirayutwatthana, N.A.; Leechanachai, P.; Dettrairat, S.; Kunachiwa, W.; Thamlikitkul, V. Efficacy and safety of zidovudine and zalcitabine combined with a combination of herbs in the treatment of HIV-infected Thai patients. Southeast Asian J. Trop. Med. Public Health, 2005, 36(3), 704-708. PMID: 16124442
  64. Durant, J.; Chantre, P.; Gonzalez, G.; Vandermander, J.; Halfon, P.; Rousse, B.; Guédon, D.; Rahelinirina, V.; Chamaret, S.; Montagnier, L.; Dellamonica, P. Efficacy and safety of Buxus sempervirens L. preparations (SPV30) in HIV-infected asymptomatic patients: A multicentre, randomized, double-blind, placebo-controlled trial. Phytomedicine, 1998, 5(1), 1-10. doi: 10.1016/S0944-7113(98)80052-4 PMID: 23195692
  65. Bodeker, G.; Carter, G.; Burford, G.; Dvorak-Little, M. HIV/AIDS: Traditional systems of health care in the management of a global epidemic. J. Altern. Complement. Med., 2006, 12(6), 563-576. doi: 10.1089/acm.2006.12.563 PMID: 16884348
  66. van den Bout-van den Beukel, C.J.P.; Koopmans, P.P.; van der Ven, A.J.A.M.; De Smet, P.A.G.M.; Burger, D.M. Possible drug-metabolism interactions of medicinal herbs with antiretroviral agents. Drug Metab. Rev., 2006, 38(3), 477-514. doi: 10.1080/03602530600754065 PMID: 16877262
  67. Holodniy, M.; Koch, J.; Mistal, M.; Schmidt, J.M.; Khandwala, A.; Pennington, J.E.; Porter, S.B. A double blind, randomized, placebo-controlled phase II study to assess the safety and efficacy of orally administered SP-303 for the symptomatic treatment of diarrhea in patients with AIDS. Am. J. Gastroenterol., 1999, 94(11), 3267-3273. doi: 10.1111/j.1572-0241.1999.01535.x PMID: 10566728
  68. Fischer, H.; Machen, T.E.; Widdicombe, J.H.; Carlson, T.J.S.; King, S.R.; Chow, J.W.S.; Illek, B. A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells. J. Ethnopharmacol., 2004, 93(2-3), 351-357. doi: 10.1016/j.jep.2004.04.005 PMID: 15234776
  69. Burack, J.H.; Cohen, M.R.; Hahn, J.A.; Abrams, D.I. Pilot randomized controlled trial of Chinese herbal treatment for HIV-associated symptoms. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 1996, 12(4), 386-393. doi: 10.1097/00042560-199608010-00009 PMID: 8673548
  70. Mills, E.; Foster, B.C.; Heeswijk, R.; Phillips, E.; Wilson, K.; Leonard, B.; Kosuge, K.; Kanfer, I. Impact of African herbal medicines on antiretroviral metabolism. AIDS, 2005, 19(1), 95-97. doi: 10.1097/00002030-200501030-00013 PMID: 15627040
  71. Available from: https://www.clinicaltrials.gov/study/NCT02140775?cond=HIV%2FAIDS&page=3&rank=22
  72. Available from: https://www.clinicaltrials.gov/study/NCT02850276?cond=HIV%2FAIDS&page=2&rank=15
  73. Available from: https://www.clinicaltrials.gov/study/NCT02898597?cond=HIV%2FAIDS&page=2&rank=16
  74. Available from: https://www.clinicaltrials.gov/study/NCT02707692?cond=HIV%2FAIDS&page=2&rank=11
  75. Available from: https://www.clinicaltrials.gov/study/NCT02291809?cond=HIV%2FAIDS&page=2&rank=14
  76. Available from: https://www.clinicaltrials.gov/study/NCT04735445?cond=HIV%2FAIDS&page=3&rank=23
  77. Available from: https://www.clinicaltrials.gov/study/NCT03661203?cond=HIV%2FAIDS&page=1&rank=7
  78. Available from: https://www.clinicaltrials.gov/study/NCT05307250?cond=HIV%2FAIDS&page=3&rank=30
  79. Available from: https://www.clinicaltrials.gov/study/NCT05423418?cond=HIV%2FAIDS&page=1&rank=9
  80. Available from: https://www.clinicaltrials.gov/study/NCT05872659?cond=HIV%2FAIDS&page=1&rank=2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers